Size Matters: Superior Efficacy of α Particle Radioimmunotherapy in Micrometastases versus Macrometastases.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40366383.
- Also identified by DOI 10.1158/1078-0432.CCR-25-0654.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiopharmaceuticals, which emit either α or β particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted α particle-emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus macrometastatic disease. See related article by Bidkar et al., p. 2963.
Medical subject headings
- Radioimmunotherapy
- Alpha Particles
- Prostatic Neoplasms
- Radiopharmaceuticals